Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Depreciation & Amortization (CF): 2016-2024

Historic Depreciation & Amortization (CF) for Whitehawk Therapeutics (WHWK) over the last 9 years, with Dec 2024 value amounting to $193,000.

  • Whitehawk Therapeutics' Depreciation & Amortization (CF) fell 88.01% to $5,600 in Q3 2025 from the same period last year, while for Sep 2025 it was $131,900, marking a year-over-year decrease of 30.69%. This contributed to the annual value of $193,000 for FY2024, which is 14.20% up from last year.
  • As of FY2024, Whitehawk Therapeutics' Depreciation & Amortization (CF) stood at $193,000, which was up 14.20% from $169,000 recorded in FY2023.
  • Whitehawk Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $193,000 for FY2024, and its period low was $9,000 during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $169,000 (2023), whereas its average is $173,667.
  • Per our database at Business Quant, Whitehawk Therapeutics' Depreciation & Amortization (CF) plummeted by 88.24% in 2020 and then skyrocketed by 1,066.67% in 2021.
  • Yearly analysis of 5 years shows Whitehawk Therapeutics' Depreciation & Amortization (CF) stood at $9,000 in 2020, then surged by 1,066.67% to $105,000 in 2021, then surged by 51.43% to $159,000 in 2022, then rose by 6.29% to $169,000 in 2023, then grew by 14.20% to $193,000 in 2024.